Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection
Copyright © 2020 Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.
PATIENTS: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.
RESULTS: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.
DISCUSSION: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:155 |
|---|---|
| Enthalten in: |
Medicina clinica - 155(2020), 4 vom: 28. Aug., Seite 159-161 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Callejas Rubio, José Luis [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.08.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2020.04.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311115993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311115993 | ||
| 003 | DE-627 | ||
| 005 | 20231225141552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2020.04.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311115993 | ||
| 035 | |a (NLM)32532461 | ||
| 035 | |a (PII)S0025-7753(20)30283-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Callejas Rubio, José Luis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection |
| 246 | 3 | 3 | |a Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19 | ||
| 520 | |a PATIENTS: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable | ||
| 520 | |a RESULTS: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival | ||
| 520 | |a DISCUSSION: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Coronavirus COVID-19 | |
| 650 | 4 | |a Cytokine release synddrome | |
| 650 | 4 | |a Hemofagocítico | |
| 650 | 4 | |a Hemophagocytic | |
| 650 | 4 | |a Síndrome de liberación de citocinas | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Luna Del Castillo, Juan de Dios |e verfasserin |4 aut | |
| 700 | 1 | |a de la Hera Fernández, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Guirao Arrabal, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Colmenero Ruiz, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ortego Centeno, Norberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 155(2020), 4 vom: 28. Aug., Seite 159-161 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:155 |g year:2020 |g number:4 |g day:28 |g month:08 |g pages:159-161 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2020.04.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 155 |j 2020 |e 4 |b 28 |c 08 |h 159-161 | ||